AstraZeneca
NEWS
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
ASCO called rare cancer treatments the “advance of the year” in oncology.
AstraZeneca underwent a restructuring earlier this year with an increased focus on oncology.
Companies share robust oncology data at annual ASCO meeting.
Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
JOBS
IN THE PRESS